Christian Andreas Radu1, Sebastian Fischer1, Yannick Diehm1, Otto Hetzel1, Florian Neubrech1, Laura Dittmar2, Christian Kleist2,3, Martha Maria Gebhard4, Peter Terness2, Ulrich Kneser1, Jurij Kiefer5. 1. Department of Hand, Plastic and Reconstructive Surgery, Burn Center, BG Trauma Center Ludwigshafen, Plastic- and Hand Surgery, University of Heidelberg, Ludwig-Guttmann-Str. 13, D-67071, Ludwigshafen, Germany. 2. Transplantation Immunology, Institute for Immunology, University of Heidelberg, Heidelberg, Germany. 3. Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany. 4. Department of Experimental Surgery, University of Heidelberg, Heidelberg, Germany. 5. Department of Hand, Plastic and Reconstructive Surgery, Burn Center, BG Trauma Center Ludwigshafen, Plastic- and Hand Surgery, University of Heidelberg, Ludwig-Guttmann-Str. 13, D-67071, Ludwigshafen, Germany. kiefer.jurij@gmail.com.
Abstract
BACKGROUND: Vascularized composite allotransplantation (VCA) is a rapidly expanding field of transplantation and provides a potential treatment for complex tissue defects. Peripheral blood mononuclear cells (PBMCs) shortly incubated with the antibiotic and chemotherapeutic agent mitomycin C (MMC) can suppress allogeneic T cell response and control allograft rejection in various organ transplantation models. MMC-incubated PBMCs (MICs) are currently being tested in a phase I clinical trial in kidney transplant patients. Previous studies with MICs in a complex VCA model showed the immunomodulatory potential of these cells. The aim of this study is to optimize and evaluate the use of MICs in combination with a standard immunosuppressive drug in VCA. METHODS: Fully mismatched rats were used as hind limb donors [Lewis (RT11)] and recipients [Brown-Norway (RT1n)]. Sixty allogeneic hind limb transplantations were performed in six groups. Group A received donor-derived MICs combined with a temporary ciclosporin A (CsA) treatment. Group B received MICs in combination with a temporarily administered reduced dose of CsA. Group C served as a control and received a standard CsA dose temporarily without an additional administration of MICs, whereas Group D was solely medicated with a reduced CsA dose. Group E received no immunosuppressive therapy, neither CsA nor MICs. Group F was given a continuous standard immunosuppressive regimen consisting of CsA and prednisolone. The endpoint of the study was the onset of allograft rejection which was assessed clinically and histologically. RESULTS: In group A and B, the rejection-free interval of the allograft was significantly prolonged to an average of 23.1 ± 1.7 and 24.7 ± 1.8 days compared to the corresponding control groups (p < 0.01). Rejection in groups C, D, and E was noted after 14.3 ± 1.1, 7.8 ± 0.7, and 6.9 ± 0.6 days. No rejection occurred in control group F during the follow-up period of 100 days. No adverse events have been noted. CONCLUSION: The findings of this study show that the combination of MICs with a temporary CsA treatment significantly prolongs the rejection-free interval in a complex VCA model. The combination of MICs with CsA showed no adverse events such as graft-versus-host disease. MICs, which are generated by a simple and reliable in vitro technique, represent a potential therapeutic tool for prolonging allograft survival through immunomodulation.
BACKGROUND: Vascularized composite allotransplantation (VCA) is a rapidly expanding field of transplantation and provides a potential treatment for complex tissue defects. Peripheral blood mononuclear cells (PBMCs) shortly incubated with the antibiotic and chemotherapeutic agent mitomycin C (MMC) can suppress allogeneic T cell response and control allograft rejection in various organ transplantation models. MMC-incubated PBMCs (MICs) are currently being tested in a phase I clinical trial in kidney transplant patients. Previous studies with MICs in a complex VCA model showed the immunomodulatory potential of these cells. The aim of this study is to optimize and evaluate the use of MICs in combination with a standard immunosuppressive drug in VCA. METHODS: Fully mismatched rats were used as hind limb donors [Lewis (RT11)] and recipients [Brown-Norway (RT1n)]. Sixty allogeneic hind limb transplantations were performed in six groups. Group A received donor-derived MICs combined with a temporary ciclosporin A (CsA) treatment. Group B received MICs in combination with a temporarily administered reduced dose of CsA. Group C served as a control and received a standard CsA dose temporarily without an additional administration of MICs, whereas Group D was solely medicated with a reduced CsA dose. Group E received no immunosuppressive therapy, neither CsA nor MICs. Group F was given a continuous standard immunosuppressive regimen consisting of CsA and prednisolone. The endpoint of the study was the onset of allograft rejection which was assessed clinically and histologically. RESULTS: In group A and B, the rejection-free interval of the allograft was significantly prolonged to an average of 23.1 ± 1.7 and 24.7 ± 1.8 days compared to the corresponding control groups (p < 0.01). Rejection in groups C, D, and E was noted after 14.3 ± 1.1, 7.8 ± 0.7, and 6.9 ± 0.6 days. No rejection occurred in control group F during the follow-up period of 100 days. No adverse events have been noted. CONCLUSION: The findings of this study show that the combination of MICs with a temporary CsA treatment significantly prolongs the rejection-free interval in a complex VCA model. The combination of MICs with CsA showed no adverse events such as graft-versus-host disease. MICs, which are generated by a simple and reliable in vitro technique, represent a potential therapeutic tool for prolonging allograft survival through immunomodulation.
Authors: Jan A Plock; Jonas T Schnider; Riccardo Schweizer; Wensheng Zhang; Wakako Tsuji; Matthias Waldner; Mario G Solari; Kacey G Marra; J Peter Rubin; Vijay S Gorantla Journal: Transplantation Date: 2017-01 Impact factor: 4.939
Authors: Sebastian Fischer; Christine G Lian; Maximilian Kueckelhaus; Terry B Strom; Elazer R Edelman; Rachel A Clark; George F Murphy; Anil K Chandraker; Leonardo V Riella; Stefan G Tullius; Bohdan Pomahac Journal: Curr Opin Organ Transplant Date: 2014-12 Impact factor: 2.640
Authors: Peter Terness; Christian Kleist; Helmut Simon; Flavius Sandra-Petrescu; Sandra Ehser; Jing-Jing Chuang; Elisabeth Mohr; Lucian Jiga; Johann Greil; Gerhard Opelz Journal: Hum Immunol Date: 2009-04-22 Impact factor: 2.850
Authors: Damon S Cooney; Eric G Wimmers; Zuhaib Ibrahim; Johanna Grahammer; Joani M Christensen; Gabriel A Brat; Lehao W Wu; Karim A Sarhane; Joseph Lopez; Christoph Wallner; Georg J Furtmüller; Nance Yuan; John Pang; Kakali Sarkar; W P Andrew Lee; Gerald Brandacher Journal: Sci Rep Date: 2016-08-11 Impact factor: 4.379
Authors: Christian Morath; Anita Schmitt; Christian Kleist; Volker Daniel; Gerhard Opelz; Caner Süsal; Eman Ibrahim; Florian Kälble; Claudius Speer; Christian Nusshag; Luiza Pego da Silva; Claudia Sommerer; Lei Wang; Ming Ni; Angela Hückelhoven-Krauss; David Czock; Uta Merle; Arianeb Mehrabi; Anja Sander; Matthes Hackbusch; Christoph Eckert; Rüdiger Waldherr; Paul Schnitzler; Carsten Müller-Tidow; Jörg D Hoheisel; Shakhawan A Mustafa; Mohamed Ss Alhamdani; Andrea S Bauer; Jochen Reiser; Martin Zeier; Michael Schmitt; Matthias Schaier; Peter Terness Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808
Authors: Jennifer Schneiderman; Longhui Qiu; Xin Yi Yeap; Xin Kang; Feibo Zheng; Junsheng Ye; Yan Xie; Jiao-Jing Wang; Yuvaraj Sambandam; James Mathew; Lin Li; Joseph Leventhal; Richard L Edelson; Zheng Jenny Zhang Journal: Sci Rep Date: 2022-05-04 Impact factor: 4.996